Cancer Cachexia: Molecular targets and pathways for diagnosis and drug intervention

Endocrine, Metabolic and Immune Disorders - Drug Targets

Volumn 12, Issue 3, 2012, Pages 247-259

  Shum, Angie M Y ^a,b,c   Polly, Patsie ^a,b,c  

^a Inflammation and Infection Research Centre   (United States)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c Department of Geriatric Medicine   (Australia)

Author keywords

Cancer cachexia; Mediators; Metabolism; Muscle wasting; Signalling; Transcription factors

Indexed keywords

ANGIOTENSIN II; CELL NUCLEUS RECEPTOR; GLUCOCORTICOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MAMMALIAN TARGET OF RAPAMYCIN; MYOCYTE ENHANCER FACTOR 2; MYOSTATIN; PROTEIN KINASE B; PROTEIN KINASE R; RETINOIC ACID RECEPTOR; SOMATOMEDIN; TRANSCRIPTION FACTOR FOXO; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VITAMIN D RECEPTOR;

ASTHENIA; CACHEXIA; CANCER PROGNOSIS; DISEASE SEVERITY; HUMAN; MUSCLE ATROPHY; MUSCLE FUNCTION; NONHUMAN; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN SYNTHESIS; QUALITY OF LIFE; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CACHEXIA; CYTOKINES; ENERGY METABOLISM; HUMANS; MOLECULAR TARGETED THERAPY; MUSCLE PROTEINS; MUSCLE, SKELETAL; NEOPLASM PROTEINS; NEOPLASMS; PROTEIN BIOSYNTHESIS; PROTEIN STABILITY;

EID: 84863577170     PISSN: 18715303     EISSN: 22123873     Source Type: Journal    
DOI: 10.2174/187153012802002910     Document Type: Review

References (172)

1. Tisdale, M. J. (2005) Molecular pathways leading to cancer cachexia. Physiology (Bethesda), 20, 340-348.
2. Fearon, K. C. (2008) Cancer cachexia: developing multimodal therapy for a multidimensional problem. Eur. J. Cancer, 44(8), 1124-1132.
3. Salpeter, S. R.; Malter, D. S.; Luo, E. J.; Lin, A. Y. and Stuart, B. (2012) Systematic Review of Cancer Presentations with a Median Survival of Six Months or Less. J. Palliat Med., 15(2), 178-185.
4. Dewys, W. D.; Begg, C.; Lavin, P. T.; Band, P. R.; Bennett, J. M.; Bertino, J. R.; Cohen, M. H.; Douglass, H. O. Jr.; Engstrom, P. F.; Ezdinli, E. Z.; Horton, J.; Johnson, G. J.; Moertel, C. G.; Oken, M. M.; Perlia, C.; Rosenbaum, C.; Silverstein, M. N.; Skeel, R. T.; Sponzo, R. W. and Tormey, D. C. (1980) Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am. J. Med., 69(4), 491-497.
5. Ross, P. J.; Ashley, S.; Norton, A.; Priest, K.; Waters, J. S.; Eisen, T.; Smith, I. E. and O'Brien, M. E. (2004) Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers? Br. J. Cancer, 90(10), 1905-1911.
6. Thivat, E.; Therondel, S.; Lapirot, O.; Abrial, C.; Gimbergues, P.; Gadea, E.; Planchat, E.; Kwiatkowski, F.; Mouret-Reynier, M. A.; Chollet, P. and Durando, X. (2010) Weight change during chemotherapy changes the prognosis in non metastatic breast cancer for the worse. BMC Cancer, 10, 648.
7. Evans, W. J.; Morley, J. E.; Argiles, J.; Bales, C.; Baracos, V.; Guttridge, D.; Jatoi, A.; Kalantar-Zadeh, K.; Lochs, H.; Mantovani, G.; Marks, D.; Mitch, W. E.; Muscaritoli, M.; Najand, A.; Ponikowski, P.; Rossi Fanelli, F.; Schambelan, M.; Schols, A.; Schuster, M.; Thomas, D.; Wolfe, R. and Anker, S. D. (2008) Cachexia: a new definition. Clin. Nutr., 27(6), 793-799.
8. Lelbach, A.; Muzes, G. and Feher, J. (2007) Current perspectives of catabolic mediators of cancer cachexia. Med. Sci. Monit., 13(9), RA168-RA173.
9. Tisdale, M. J. (2002) Cachexia in cancer patients. Nat. Rev. Cancer, 2(11), 862-871.
10. Argiles, J. M.; Alvarez, B. and Lopez-Soriano, F. J. (1997) The metabolic basis of cancer cachexia. Med. Res. Rev., 17(5), 477-498.
11. Frosig, C. and Richter, E. A. (2009) Improved insulin sensitivity after exercise: focus on insulin signalling. Obesity (Silver Spring), 17(Suppl 3), S15-S20.
12. Pedersen, B. K. and Febbraio, M. A. (2008) Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol. Rev., 88 (4), 1379-1406.
13. Schiaffino, S. (2010) Fibre types in skeletal muscle: a personal account. Acta. Physiol. (Oxf)., 199(4), 451-463.
14. Costelli, P.; Bossola, M.; Muscaritoli, M.; Grieco, G.; Bonelli, G.; Bellantone, R.; Doglietto, G. B.; Baccino, F. M. and Rossi, F. F. (2002) Anticytokine treatment prevents the increase in the activity of ATP-ubiquitin-and Ca(2+)-dependent proteolytic systems in the muscle of tumour-bearing rats. Cytokine, 19(1), 1-5.
15. Clark, C. M. and Goodlad, G. A. (1971) Depletion of proteins of phasic and tonic muscles in tumour-bearing rats. Eur. J. Cancer, 7(1), 3-9.
16. Tiao, G.; Lieberman, M.; Fischer, J. E. and Hasselgren, P. O. (1997) Intracellular regulation of protein degradation during sepsis is different in fast-and slow-twitch muscle. Am. J. Physiol., 272(3 Pt 2), R849-R856.
17. Fang, C. H.; Li, B. G.; Tiao, G.; Wang, J. J.; Fischer, J. E. and Hasselgren, P. O. (1998) The molecular regulation of protein breakdown following burn injury is different in fast-and slowtwitch skeletal muscle. Int. J. Mol. Med., 1(1), 163-169.
18. Acharyya, S.; Butchbach, M. E.; Sahenk, Z.; Wang, H.; Saji, M.; Carathers, M.; Ringel, M. D.; Skipworth, R. J.; Fearon, K. C.; Hollingsworth, M. A.; Muscarella, P.; Burghes, A. H.; Rafael-Fortney, J. A. and Guttridge, D. C. (2005) Dystrophin glycoprotein complex dysfunction: a regulatory link between muscular dystrophy and cancer cachexia. Cancer Cell, 8(5), 421-432.
19. Fearon, K. C. and Preston, T. (1990) Body composition in cancer cachexia. Infusionstherapie, 17(Suppl 3), 63-66.
20. Zhou, X.; Wang, J. L.; Lu, J.; Song, Y.; Kwak, K. S.; Jiao, Q.; Rosenfeld, R.; Chen, Q.; Boone, T.; Simonet, W. S.; Lacey, D. L.; Goldberg, A. L. and Han, H. Q. (2010) Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell, 142(4), 531-543.
21. Diffee, G. M.; Kalfas, K.; Al-Majid, S. and McCarthy, D. O. (2002) Altered expression of skeletal muscle myosin isoforms in cancer cachexia. Am. J. Physiol. Cell Physiol., 283(5), C1376-C1382.
22. Mehl, K. A.; Davis, J. M.; Berger, F. G. and Carson, J. A. (2005) Myofiber degeneration/regeneration is induced in the cachectic ApcMin/+ mouse. J. Appl. Physiol., 99(6), 2379-2387.
23. Argiles, J. M. and Lopez-Soriano, F. J. (1999) The role of cytokines in cancer cachexia. Med. Res. Rev., 19(3), 223-248.
24. Balkwill, F. and Mantovani, A. (2001) Inflammation and cancer: back to Virchow? Lancet, 357(9255), 539-545.
25. Figueras, M.; Busquets, S.; Carbo, N.; Almendro, V.; Argiles, J. M. and Lopez-Soriano, F. J. (2005) Cancer cachexia results in an increase in TNF-alpha receptor gene expression in both skeletal muscle and adipose tissue. Int. J. Oncol., 27(3), 855-860.
26. Baracos, V. E. (2000) Regulation of skeletal-muscle-protein turnover in cancer-associated cachexia. Nutrition, 16(10), 1015-1018.
27. Krzystek-Korpacka, M.; Matusiewicz, M.; Diakowska, D.; Grabowski, K.; Blachut, K.; Kustrzeba-Wojcicka, I. and Banas, T. (2007) Impact of weight loss on circulating IL-1, IL-6, IL-8, TNFalpha, VEGF-A, VEGF-C and midkine in gastroesophageal cancer patients. Clin. Biochem., 40(18), 1353-1360.
28. Bossola, M.; Muscaritoli, M.; Bellantone, R.; Pacelli, F.; Cascino, A.; Sgadari, A.; Battaglia, F.; Piccioni, E.; Scambia, G.; Doglietto, G. B.; Rossi, F. F. (2000) Serum tumour necrosis factor-alpha levels in cancer patients are discontinuous and correlate with weight loss. Eur. J. Clin. Invest., 30(12), 1107-1112.
29. Maltoni, M.; Fabbri, L.; Nanni, O.; Scarpi, E.; Pezzi, L.; Flamini, E.; Riccobon, A.; Derni, S.; Pallotti, G. and Amadori, D. (1997) Serum levels of tumour necrosis factor alpha and other cytokines do not correlate with weight loss and anorexia in cancer patients. Support Care Cancer, 5(2), 130-135.
30. Karayiannakis, A. J.; Syrigos, K. N.; Polychronidis, A.; Pitiakoudis, M.; Bounovas, A. and Simopoulos, K. (2001) Serum levels of tumor necrosis factor-alpha and nutritional status in pancreatic cancer patients. Anticancer Res., 21(2B), 1355-1358.
31. Costelli, P.; Carbo, N.; Tessitore, L.; Bagby, G. J.; Lopez-Soriano, F. J.; Argiles, J. M. and Baccino, F. M. (1993) Tumor necrosis factor-alpha mediates changes in tissue protein turnover in a rat cancer cachexia model. J. Clin. Invest., 92(6), 2783-2789.
32. Dezube, B. J.; Sherman, M. L.; Fridovich-Keil, J. L.; Allen-Ryan, J. and Pardee, A. B. (1993) Down-regulation of tumor necrosis factor expression by pentoxifylline in cancer patients: a pilot study. Cancer Immunol. Immunother., 36(1), 57-60.
33. Goldberg, R. M.; Loprinzi, C. L.; Mailliard, J. A.; O'Fallon, J. R.; Krook, J. E.; Ghosh, C.; Hestorff, R. D.; Chong, S. F.; Reuter, N. F. and Shanahan, T. G. (1995) Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebocontrolled trial. J. Clin. Oncol., 13(11), 2856-2859.
34. Llovera, M.; Carbo, N.; Garcia-Martinez, C.; Costelli, P.; Tessitore, L.; Baccino, F. M.; Agell, N.; Bagby, G. J.; Lopez-Soriano, F. J. and Argiles, J. M. (1996) Anti-TNF treatment reverts increased muscle ubiquitin gene expression in tumour-bearing rats. Biochem. Biophys. Res. Commun., 221(3), 653-655.
35. Gelin, J.; Moldawer, L. L.; Lonnroth, C.; Sherry, B.; Chizzonite, R. and Lundholm, K. (1991) Role of endogenous tumor necrosis factor alpha and interleukin 1 for experimental tumor growth and the development of cancer cachexia. Cancer Res., 51(1), 415-421.
36. Carson, J. A. and Baltgalvis, K. A. (2010) Interleukin 6 as a key regulator of muscle mass during cachexia. Exerc. Sport. Sci. Rev., 38(4), 168-176.
37. Strassmann, G.; Fong, M.; Kenney, J. S. and Jacob, C. O. (1992) Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J. Clin. Invest., 89(5), 1681-1684.
38. Baltgalvis, K. A.; Berger, F. G.; Pena, M. M.; Davis, J. M.; Muga, S. J. and Carson, J. A. (2008) Interleukin-6 and cachexia in ApcMin/+ mice. Am. J. Physiol. Regul. Integr. Comp. Physiol., 294(2), R393-401.
39. Iwase, S.; Murakami, T.; Saito, Y. and Nakagawa, K. (2004) Steep elevation of blood interleukin-6 (IL-6) associated only with late stages of cachexia in cancer patients. Eur. Cytokine Netw., 15(4), 312-316.
40. Scott, H. R.; McMillan, D. C.; Crilly, A.; McArdle, C. S. and Milroy, R. (1996) The relationship between weight loss and interleukin 6 in non-small-cell lung cancer. Br. J. Cancer, 73(12), 1560-1562.
41. Kuroda, K.; Nakashima, J.; Kanao, K.; Kikuchi, E.; Miyajima, A.; Horiguchi, Y.; Nakagawa, K.; Oya, M.; Ohigashi, T. and Murai, M. (2007) Interleukin 6 is associated with cachexia in patients with prostate cancer. Urology, 69(1), 113-117.
42. Strassmann, G.; Jacob, C. O.; Evans, R.; Beall, D. and Fong, M. (1992) Mechanisms of experimental cancer cachexia. Interaction between mononuclear phagocytes and colon-26 carcinoma and its relevance to IL-6-mediated cancer cachexia. J. Immunol., 148(11), 3674-3678.
43. Strassmann, G.; Masui, Y.; Chizzonite, R. and Fong, M. (1993) Mechanisms of experimental cancer cachexia. Local involvement of IL-1 in colon-26 tumor. J. Immunol., 150(6), 2341-2345.
44. Tamura, S.; Ouchi, K. F.; Mori, K.; Endo, M.; Matsumoto, T.; Eda, H.; Tanaka, Y.; Ishitsuka, H.; Tokita, H. and Yamaguchi, K. (1995) Involvement of human interleukin 6 in experimental cachexia induced by a human uterine cervical carcinoma xenograft. Clin. Cancer Res., 1(11), 1353-1358.
45. Fujimoto-Ouchi, K.; Tamura, S.; Mori, K.; Tanaka, Y. and Ishitsuka, H. (1995) Establishment and characterization of cachexiainducing and-non-inducing clones of murine colon 26 carcinoma. Int. J. Cancer, 61(4), 522-528.
46. Enomoto, A.; Rho, M. C.; Fukami, A.; Hiraku, O.; Komiyama, K. and Hayashi, M. (2004) Suppression of cancer cachexia by 20S,21-epoxy-resibufogenin-3-acetate-a novel nonpeptide IL-6 receptor antagonist. Biochem. Biophys. Res. Commun., 323(3), 1096-1102.
47. Fujita, J.; Tsujinaka, T.; Yano, M.; Ebisui, C.; Saito, H.; Katsume, A.; Akamatsu, K.; Ohsugi, Y.; Shiozaki, H. and Monden, M. (1996) Anti-interleukin-6 receptor antibody prevents muscle atrophy in colon-26 adenocarcinoma-bearing mice with modulation of lysosomal and ATP-ubiquitin-dependent proteolytic pathways. Int. J. Cancer, 68(5), 637-643.
48. Strassmann, G.; Fong, M.; Freter, C. E.; Windsor, S.; D'Alessandro, F. and Nordan, R. P. (1993) Suramin interferes with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo. J. Clin. Invest., 92(5), 2152-2159.
49. Zaki, M. H.; Nemeth, J. A. and Trikha, M. (2004) CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice. Int. J. Cancer, 111(4), 592-595.
50. Tanaka, K.; Urata, N.; Mikami, M.; Ogasawara, M.; Matsunaga, T.; Terashima, N. and Suzuki, H. (2007) Effect of iguratimod and other anti-rheumatic drugs on adenocarcinoma colon 26-induced cachexia in mice. Inflamm. Res., 56(1), 17-23.
51. Kuroda, K.; Horiguchi, Y.; Nakashima, J.; Kikuchi, E.; Kanao, K.; Miyajima, A.; Ohigashi, T.; Umezawa, K. and Murai, M. (2005) Prevention of cancer cachexia by a novel nuclear factor {kappa}B inhibitor in prostate cancer. Clin. Cancer Res., 11(15), 5590-5594.
52. Nai, Y. J.; Jiang, Z. W.; Wang, Z. M.; Li, N. and Li, J. S. (2007) Prevention of cancer cachexia by pyrrolidine dithiocarbamate (PDTC) in colon 26 tumor-bearing mice. JPEN J. Parenter Enteral. Nutr., 31(1), 18-25.
53. Bayliss, T. J.; Smith, J. T.; Schuster, M.; Dragnev, K. H. and Rigas, J. R. (2011) A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer. Expert. Opin. Biol. Ther., 11(12), 1663-1668.
54. Todorov, P.; Cariuk, P.; McDevitt, T.; Coles, B.; Fearon, K.; Tisdale, M. (1996) Characterization of a cancer cachectic factor. Nature, 379(6567), 739-742.
55. Wigmore, S. J.; Todorov, P. T.; Barber, M. D.; Ross, J. A.; Tisdale, M. J. and Fearon, K. C. (2000) Characteristics of patients with pancreatic cancer expressing a novel cancer cachectic factor. Br. J. Surg., 87(1), 53-58.
56. Cabal-Manzano, R.; Bhargava, P.; Torres-Duarte, A.; Marshall, J. and Wainer, I. W. (2001) Proteolysis-inducing factor is expressed in tumours of patients with gastrointestinal cancers and correlates with weight loss. Br. J. Cancer, 84(12), 1599-1601.
57. Wang, Q.; Lu, J. B.; Wu, B. and Hao, L. Y. (2010) Expression and clinicopathologic significance of proteolysis-inducing factor in non-small-cell lung cancer: an immunohistochemical analysis. Clin. Lung Cancer, 11(5), 346-351.
58. Williams, M. L.; Torres-Duarte, A.; Brant, L. J.; Bhargava, P.; Marshall, J. and Wainer, I. W. (2004) The relationship between a urinary cachectic factor and weight loss in advanced cancer patients. Cancer Invest., 22(6), 866-870.
59. Wieland, B. M.; Stewart, G. D.; Skipworth, R. J.; Sangster, K.; Fearon, K. C.; Ross, J. A.; Reiman, T. J.; Easaw, J.; Mourtzakis, M.; Kumar, V.; Pak, B. J.; Calder, K.; Filippatos, G.; Kremastinos, D. T.; Palcic, M. and Baracos, V. E. (2007) Is there a human homologue to the murine proteolysis-inducing factor? Clin. Cancer Res., 13(17), 4984-4992.
60. Jatoi, A.; Foster, N.; Wieland, B.; Murphy, B.; Nikcevich, D.; LaPlant, B.; Palcic, M. M. and Baracos, V. (2006) The proteolysisinducing factor: in search of its clinical relevance in patients with metastatic gastric/esophageal cancer. Dis. Esophagus, 19(4), 241-247.
61. Tisdale, M. J. (2008) Re: Wieland BM, et al. Is there a human homologue to the murine proteolysis-inducing factor? Clin. Cancer Res., 14(7), 2245; author reply 2245-2246.
62. Mirza, K. A.; Wyke, S. M. and Tisdale, M. J. (2011) Attenuation of muscle atrophy by an N-terminal peptide of the receptor for proteolysis-inducing factor (PIF). Br. J. Cancer, 105(1), 83-88.
63. Lorite, M. J.; Thompson, M. G.; Drake, J. L.; Carling, G. and Tisdale, M. J. (1998) Mechanism of muscle protein degradation induced by a cancer cachectic factor. Br. J. Cancer, 78(7), 850-856.
64. Hussey, H. J. and Tisdale, M. J. (1999) Effect of a cachectic factor on carbohydrate metabolism and attenuation by eicosapentaenoic acid. Br. J. Cancer, 80(8), 1231-1235.
65. Watchorn, T. M.; Waddell, I.; Dowidar, N. and Ross, J. A. (2001) Proteolysis-inducing factor regulates hepatic gene expression via the transcription factors NF-(kappa)B and STAT3. FASEB J., 15 (3), 562-564.
66. Todorov, P. T.; Wyke, S. M. and Tisdale, M. J. (2007) Identification and characterization of a membrane receptor for proteolysisinducing factor on skeletal muscle. Cancer Res., 67(23), 11419-11427.
67. Jones, J. I. and Clemmons, D. R. (1995) Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev., 16(1), 3-34.
68. Lawrence, M. C.; McKern, N. M. and Ward, C. W. (2007) Insulin receptor structure and its implications for the IGF-1 receptor. Curr. Opin. Struct. Biol., 17(6), 699-705.
69. Velloso, C. P. (2008) Regulation of muscle mass by growth hormone and IGF-I. Br. J. Pharmacol., 154(3), 557-568.
70. Simons, J. P.; Schols, A. M.; Buurman, W. A. and Wouters, E. F. (1999) Weight loss and low body cell mass in males with lung cancer: relationship with systemic inflammation, acute-phase response, resting energy expenditure, and catabolic and anabolic hormones. Clin. Sci. (Lond)., 97(2), 215-223.
71. Costelli, P.; Muscaritoli, M.; Bossola, M.; Penna, F.; Reffo, P.; Bonetto, A.; Busquets, S.; Bonelli, G.; Lopez-Soriano, F. J.; Doglietto, G. B.; Argiles, J. M.; Baccino, F. M. and Rossi, F.F. (2006) IGF-1 is downregulated in experimental cancer cachexia. Am. J. Physiol. Regul. Integr. Comp. Physiol., 291(3), R674-R683.
72. Lazarus, D. D.; Kambayashi, T.; Lowry, S. and Strassmann, G. (1996) The lack of an effect by insulin or insulin-like growth factor-1 in attenuating colon-2-mediated cancer cachexia. Cancer Lett., 103(1), 71-77.
73. Tessitore, L.; Costelli, P. and Baccino, F. M. (1994) Pharmacological interference with tissue hypercatabolism in tumour-bearing rats. Biochem. J., 299(Pt 1), 71-78.
74. Dehoux, M.; Gobier, C.; Lause, P.; Bertrand, L.; Ketelslegers, J. M. and Thissen, J. P. (2007) IGF-I does not prevent myotube atrophy caused by proinflammatory cytokines despite activation of Akt/Foxo and GSK-3beta pathways and inhibition of atrogin-1 mRNA. Am. J. Physiol. Endocrinol. Metab., 292(1), E145-E150.
75. Russell, S. T. and Tisdale, M. J. (2005) The role of glucocorticoids in the induction of zinc-alpha2-glycoprotein expression in adipose tissue in cancer cachexia. Br. J. Cancer, 92(5), 876-881.
76. Knapp, M. L.; Al-Sheibani, S.; Riches, P. G.; Hanham, I. W. and Phillips, R. H. (1991) Hormonal factors associated with weight loss in patients with advanced breast cancer. Ann. Clin. Biochem., 28 (Pt 5), 480-486.
77. Svaninger, G.; Gelin, J. and Lundholm, K. (1987) Tumor-host wasting not explained by adrenal hyperfunction in tumor-bearing animals. J. Natl. Cancer Inst., 79(5), 1135-1141.
78. Schakman, O.; Gilson, H. and Thissen, J. P. (2008) Mechanisms of glucocorticoid-induced myopathy. J. Endocrinol., 197(1), 1-10.
79. Hasselgren, P. O. (1999) Glucocorticoids and muscle catabolism. Curr. Opin. Clin. Nutr. Metab. Care, 2(3), 201-205.
80. Sandri, M.; Sandri, C.; Gilbert, A.; Skurk, C.; Calabria, E.; Picard, A.; Walsh, K.; Schiaffino, S.; Lecker, S. H.; and Goldberg, A. L. (2004) Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell, 117 (3), 399-412.
81. Shah, O. J.; Kimball, S. R. and Jefferson, L. S. (2000) Glucocorticoids abate p70(S6k) and eIF4E function in L6 skeletal myoblasts. Am. J. Physiol. Endocrinol. Metab., 279(1), E74-E82.
82. Shah, O. J.; Kimball, S. R. and Jefferson, L. S. (2000) Acute attenuation of translation initiation and protein synthesis by glucocorticoids in skeletal muscle. Am. J. Physiol. Endocrinol. Metab., 278(1), E76-E82.
83. Li, B. G.; Hasselgren, P. O.; Fang, C. H. and Warden, G. D. (2004) Insulin-like growth factor-I blocks dexamethasone-induced protein degradation in cultured myotubes by inhibiting multiple proteolytic pathways: 2002 ABA paper. J. Burn. Care Rehabil., 25(1), 112-118.
84. Sacheck, J. M.; Ohtsuka, A.; McLary, S. C. and Goldberg, A. L. (2004) IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1. Am. J. Physiol. Endocrinol. Metab., 287(4), E591-601.
85. Gayan-Ramirez, G.; Vanderhoydonc, F.; Verhoeven, G. and Decramer, M. (1999) Acute treatment with corticosteroids decreases IGF-1 and IGF-2 expression in the rat diaphragm and gastrocnemius. Am. J. Respir. Crit. Care Med., 159(1), 283-289.
86. Ma, K.; Mallidis, C.; Bhasin, S.; Mahabadi, V.; Artaza, J.; Gonzalez-Cadavid, N.; Arias, J. and Salehian, B. (2003) Glucocorticoid-induced skeletal muscle atrophy is associated with upregulation of myostatin gene expression. Am. J. Physiol. Endocrinol. Metab., 285(2), E363-371.
87. Gilson, H.; Schakman, O.; Combaret, L.; Lause, P.; Grobet, L.; Attaix, D.; Ketelslegers, J. M. and Thissen, J. P. (2007) Myostatin gene deletion prevents glucocorticoid-induced muscle atrophy. Endocrinology, 148(1), 452-460.
88. Dekhuijzen, P. N.; Gayan-Ramirez, G.; Bisschop, A.; De Bock, V.; Dom, R. and Decramer, M. (1995) Corticosteroid treatment and nutritional deprivation cause a different pattern of atrophy in rat diaphragm. J. Appl. Physiol., 78(2), 629-637.
89. Fournier, M.; Huang, Z. S.; Li, H.; Da, X.; Cercek, B. and Lewis, M. I. (2003) Insulin-like growth factor I prevents corticosteroidinduced diaphragm muscle atrophy in emphysematous hamsters. Am. J. Physiol. Regul. Integr. Comp. Physiol., 285(1), R34-43.
90. Brink, M.; Wellen, J. and Delafontaine, P. (1996) Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism. J. Clin. Invest., 97(11), 2509-2516.
91. Brink, M.; Price, S. R.; Chrast, J.; Bailey, J. L.; Anwar, A.; Mitch, W. E. and Delafontaine, P. (2001) Angiotensin II induces skeletal muscle wasting through enhanced protein degradation and downregulates autocrine insulin-like growth factor I. Endocrinology, 142(4), 1489-1496.
92. Russell, S. T.; Sanders, P. M. and Tisdale, M. J. (2006) Angiotensin II directly inhibits protein synthesis in murine myotubes. Cancer Lett., 231(2), 290-294.
93. Song, Y. H.; Li, Y.; Du, J.; Mitch, W. E.; Rosenthal, N. and Delafontaine, P. (2005) Muscle-specific expression of IGF-1 blocks angiotensin II-induced skeletal muscle wasting. J. Clin. Invest., 115(2), 451-458.
94. Yoshida, T.; Semprun-Prieto, L.; Sukhanov, S. and Delafontaine, P. (2010) IGF-1 prevents ANG II-induced skeletal muscle atrophy via Akt-and Foxo-dependent inhibition of the ubiquitin ligase atrogin-1 expression. Am. J. Physiol. Heart Circ. Physiol., 298(5), H1565-H1570.
95. Nagaya, N.; Uematsu, M.; Kojima, M.; Date, Y.; Nakazato, M.; Okumura, H.; Hosoda, H.; Shimizu, W.; Yamagishi, M.; Oya, H.; Koh, H.; Yutani, C. and Kangawa, K. (2001) Elevated circulating level of ghrelin in cachexia associated with chronic heart failure: relationships between ghrelin and anabolic/catabolic factors. Circulation, 104(17), 2034-2038.
96. Adigun, A. Q. and Ajayi, A. A. (2001) The effects of enalapril-digoxindiuretic combination therapy on nutritional and anthropometric indices in chronic congestive heart failure: preliminary findings in cardiac cachexia. Eur. J. Heart Fail., 3(3), 359-363.
97. Sanders, P. M.; Russell, S. T. and Tisdale, M. J. (2005) Angiotensin II directly induces muscle protein catabolism through the ubiquitin-proteasome proteolytic pathway and may play a role in cancer cachexia. Br. J. Cancer, 93(4), 425-434.
98. Kollias, H. D. and McDermott, J. C. (2008) Transforming growth factor-beta and myostatin signalling in skeletal muscle. J. Appl. Physiol., 104(3), 579-587.
99. Zimmers, T. A.; Davies, M. V.; Koniaris, L. G.; Haynes, P.; Esquela, A. F.; Tomkinson, K. N.; McPherron, A. C.; Wolfman, N. M. and Lee, S. J. (2002) Induction of cachexia in mice by systemically administered myostatin. Science, 296(5572), 1486-1488.
100. McFarlane, C.; Plummer, E.; Thomas, M.; Hennebry, A.; Ashby, M.; Ling, N.; Smith, H.; Sharma, M. and Kambadur, R. (2006) Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-kappaB-independent, FoxO1-dependent mechanism. J. Cell Physiol., 209(2), 501-514.
101. Costelli, P.; Muscaritoli, M.; Bonetto, A.; Penna, F.; Reffo, P.; Bossola, M.; Bonelli, G.; Doglietto, G. B.; Baccino, F. M. and Rossi, F.F. (2008) Muscle myostatin signalling is enhanced in experimental cancer cachexia. Eur. J. Clin. Invest., 38(7), 531-538.
102. Liu, C. M.; Yang, Z.; Liu, C. W.; Wang, R.; Tien, P.; Dale, R. and Sun, L. Q. (2008) Myostatin antisense RNA-mediated muscle growth in normal and cancer cachexia mice. Gene Ther., 15(3), 155-160.
103. Murphy, K. T.; Chee, A.; Gleeson, B. G.; Naim, T.; Swiderski, K.; Koopman, R. and Lynch, G. S. (2011) Antibody-directed myostatin inhibition enhances muscle mass and function in tumor-bearing mice. Am. J. Physiol. Regul. Integr. Comp. Physiol., 301(3), R716-R726.
104. Benny, K. M. E.; Aydogdu, T.; Link, M. J.; Pons, M.; Koniaris, L. G. and Zimmers, T. A. (2010) Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. Biochem. Biophys. Res. Commun., 391(3), 1548-1554.
105. Gilson, H.; Schakman, O.; Kalista, S.; Lause, P.; Tsuchida, K. and Thissen, J. P. (2009) Follistatin induces muscle hypertrophy through satellite cell proliferation and inhibition of both myostatin and activin. Am. J. Physiol. Endocrinol. Metab., 297(1), E157-E164.
106. Pallafacchina, G.; Calabria, E.; Serrano, A. L.; Kalhovde, J. M. and Schiaffino, S. (2002) A protein kinase B-dependent and rapamycinsensitive pathway controls skeletal muscle growth but not fiber type specification. Proc. Natl. Acad. Sci. USA, 99(14), 9213-9218.
107. Bodine, S. C. (2006) mTOR signalling and the molecular adaptation to resistance exercise. Med. Sci. Sports Exerc., 38(11), 1950-1957.
108. Stitt, T. N.; Drujan, D.; Clarke, B. A.; Panaro, F.; Timofeyva, Y.; Kline, W. O.; Gonzalez, M.; Yancopoulos, G. D. and Glass, D. J. (2004) The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol. Cell, 14(3), 395-403.
109. Asp, M. L.; Tian, M.; Wendel, A. A. and Belury, M. A. (2010) Evidence for the contribution of insulin resistance to the development of cachexia in tumor-bearing mice. Int. J. Cancer, 126(3), 756-763.
110. Schmitt, T. L.; Martignoni, M. E.; Bachmann, J.; Fechtner, K.; Friess, H.; Kinscherf, R. and Hildebrandt, W. (2007) Activity of the Akt-dependent anabolic and catabolic pathways in muscle and liver samples in cancer-related cachexia. J. Mol. Med., 85(6), 647-654.
111. Penna, F.; Bonetto, A.; Muscaritoli, M.; Costamagna, D.; Minero, V. G.; Bonelli, G.; Rossi Fanelli, F.; Baccino, F. M. and Costelli, P. (2010) Muscle atrophy in experimental cancer cachexia: is the IGF-1 signalling pathway involved? Int. J. Cancer, 127(7), 1706-1717.
112. Sengupta, S.; Peterson, T. R. and Sabatini, D. M. (2010) Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol. Cell, 40(2), 310-322.
113. Nieto-Vazquez, I.; Fernandez-Veledo, S.; de Alvaro, C. and Lorenzo, M. (2008) Dual role of interleukin-6 in regulating insulin sensitivity in murine skeletal muscle. Diabetes, 57(12), 3211-3221.
114. Ueki, K.; Kondo, T. and Kahn, C. R. (2004) Suppressor of cytokine signalling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol. Cell Biol., 24(12), 5434-5446.
115. Trendelenburg, A. U.; Meyer, A.; Rohner, D.; Boyle, J.; Hatakeyama, S. and Glass, D. J. (2009) Myostatin reduces Akt/TORC1/p70S6K signalling, inhibiting myoblast differentiation and myotube size. Am. J. Physiol. Cell Physiol., 296(6), C1258-1270.
116. Ji, M.; Zhang, Q.; Ye, J.; Wang, X.; Yang, W. and Zhu, D. (2008) Myostatin induces p300 degradation to silence cyclin D1 expression through the PI3K/PTEN/Akt pathway. Cell Signal., 20(8), 1452-1458.
117. Hittel, D. S.; Axelson, M.; Sarna, N.; Shearer, J.; Huffman, K. M. and Kraus, W. E. (2010) Myostatin decreases with aerobic exercise and associates with insulin resistance. Med. Sci. Sports Exerc., 42(11), 2023-2029.
118. Amirouche, A.; Durieux, A. C.; Banzet, S.; Koulmann, N.; Bonnefoy, R.; Mouret, C.; Bigard, X.; Peinnequin, A. and Freyssenet, D. (2009) Down-regulation of Akt/mammalian target of rapamycin signalling pathway in response to myostatin overexpression in skeletal muscle. Endocrinology, 150(1), 286-294.
119. Sartori, R.; Milan, G.; Patron, M.; Mammucari, C.; Blaauw, B.; Abraham, R. and Sandri, M. (2009) Smad2 and 3 transcription factors control muscle mass in adulthood. Am. J. Physiol. Cell Physiol., 296(6), C1248-C1257.
120. Zhu, X.; Topouzis, S.; Liang, L. F. and Stotish, R. L. (2004) Myostatin signalling through Smad2, Smad3 and Smad4 is regulated by the inhibitory Smad7 by a negative feedback mechanism. Cytokine, 26(6), 262-272.
121. Azar, R.; Alard, A.; Susini, C.; Bousquet, C. and Pyronnet, S. (2009) 4E-BP1 is a target of Smad4 essential for TGFbetamediated inhibition of cell proliferation. EMBO J., 28(22), 3514-3522.
122. Calegari, V. C.; Alves, M.; Picardi, P. K.; Inoue, R. Y.; Franchini, K. G.; Saad, M. J. and Velloso, L. A. (2005) Suppressor of cytokine signalling-3 Provides a novel interface in the cross-talk between angiotensin II and insulin signalling systems. Endocrinology, 146(2), 579-588.
123. Hu, Z.; Wang, H.; Lee, I. H.; Du, J. and Mitch, W. E. (2009) Endogenous glucocorticoids and impaired insulin signalling are both required to stimulate muscle wasting under pathophysiological conditions in mice. J. Clin. Invest., 119(10), 3059-3069.
124. Wang, H.; Kubica, N.; Ellisen, L. W.; Jefferson, L. S. and Kimball, S. R. (2006) Dexamethasone represses signalling through the mammalian target of rapamycin in muscle cells by enhancing expression of REDD1. J. Biol. Chem., 281(51), 39128-39134.
125. Shimizu, N.; Yoshikawa, N.; Ito, N.; Maruyama, T.; Suzuki, Y.; Takeda, S.; Nakae, J.; Tagata, Y.; Nishitani, S.; Takehana, K.; Sano, M.; Fukuda, K.; Suematsu, M.; Morimoto, C. and Tanaka, H. (2011) Crosstalk between glucocorticoid receptor and nutritional sensor mTOR in skeletal muscle. Cell Metab., 13(2), 170-182.
126. DeYoung, M. P.; Horak, P.; Sofer, A.; Sgroi, D. and Ellisen, L. W. (2008) Hypoxia regulates TSC1/2-mTOR signalling and tumor suppression through REDD1-mediated 14-3-3 shuttling. Genes Dev., 22(2), 239-251.
127. Blaauw, B.; Mammucari, C.; Toniolo, L.; Agatea, L.; Abraham, R.; Sandri, M.; Reggiani, C. and Schiaffino, S. (2008) Akt activation prevents the force drop induced by eccentric contractions in dystrophin-deficient skeletal muscle. Hum. Mol. Genet., 17(23), 3686-3696.
128. Lecker, S. H.; Jagoe, R. T.; Gilbert, A.; Gomes, M.; Baracos, V.; Bailey, J.; Price, S. R.; Mitch, W. E. and Goldberg, A. L. (2004) Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J., 18(1), 39-51.
129. Zhao, J.; Brault, J. J.; Schild, A.; Cao, P.; Sandri, M.; Schiaffino, S.; Lecker, S. H. and Goldberg, A. L. (2007) FoxO3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells. Cell. Metab., 6(6), 472-483.
130. Wing, S. S.; Lecker, S. H. and Jagoe, R. T. (2011) Proteolysis in illness-associated skeletal muscle atrophy: from pathways to networks. Crit. Rev. Clin. Lab Sci., 48(2), 49-70.
131. Mammucari, C.; Milan, G.; Romanello, V.; Masiero, E.; Rudolf, R.; Del Piccolo, P.; Burden, S. J.; Di Lisi, R.; Sandri, C.; Zhao, J.; Goldberg, A. L.; Schiaffino, S. and Sandri, M. (2007) FoxO3 controls autophagy in skeletal muscle in vivo. Cell. Metab., 6(6), 458-471.
132. Liu, C. M.; Yang, Z.; Liu, C. W.; Wang, R.; Tien, P.; Dale, R. and Sun, L. Q. (2007) Effect of RNA oligonucleotide targeting Foxo-1 on muscle growth in normal and cancer cachexia mice. Cancer Gene Ther., 14 (12), 945-952.
133. Cho, J. E.; Fournier, M.; Da, X. and Lewis, M. I. (2010) Time course expression of Foxo transcription factors in skeletal muscle following corticosteroid administration. J. Appl. Physiol., 108(1), 137-145.
134. Zheng, B.; Ohkawa, S.; Li, H.; Roberts-Wilson, T. K. and Price, S. R. (2010) FOXO3a mediates signalling crosstalk that coordinates ubiquitin and atrogin-1/MAFbx expression during glucocorticoidinduced skeletal muscle atrophy. FASEB J., 24(8), 2660-2669.
135. Li, H.; Malhotra, S. and Kumar, A. (2008) Nuclear factor-kappa B signalling in skeletal muscle atrophy. J. Mol. Med., 86(10), 1113-1126.
136. Guttridge, D. C.; Mayo, M. W.; Madrid, L. V.; Wang, C. Y. and Baldwin, A. S. Jr. (2000) NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science, 289(5488), 2363-2366.
137. Cai, D.; Frantz, J. D.; Tawa, N. E. Jr.; Melendez, P. A.; Oh, B. C.; Lidov, H. G.; Hasselgren, P. O.; Frontera, W. R.; Lee, J.; Glass, D. J. and Shoelson, S. E. (2004) IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell, 119(2), 285-298.
138. Rhoads, M. G.; Kandarian, S. C.; Pacelli, F.; Doglietto, G. B. and Bossola, M. (2010) Expression of NF-kappaB and IkappaB proteins in skeletal muscle of gastric cancer patients. Eur. J. Cancer, 46(1), 191-197.
139. Wyke, S. M. and Tisdale, M. J. (2005) NF-kappaB mediates proteolysis-inducing factor induced protein degradation and expression of the ubiquitin-proteasome system in skeletal muscle. Br. J. Cancer, 92(4), 711-721.
140. Wyke, S. M.; Russell, S. T. and Tisdale, M. J. (2004) Induction of proteasome expression in skeletal muscle is attenuated by inhibitors of NF-kappaB activation. Br. J. Cancer, 91(9), 1742-1750.
141. Whitehouse, A. S. and Tisdale, M. J. (2003) Increased expression of the ubiquitin-proteasome pathway in murine myotubes by proteolysis-inducing factor (PIF) is associated with activation of the transcription factor NF-kappaB. Br. J. Cancer, 89(6), 1116-1122.
142. Russell, S. T.; Wyke, S. M. and Tisdale, M. J. (2006) Mechanism of induction of muscle protein degradation by angiotensin II. Cell Signal, 18(7), 1087-1096.
143. Li, Y. P.; Schwartz, R. J.; Waddell, I. D.; Holloway, B. R. and Reid, M. B. (1998) Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-kappaB activation in response to tumor necrosis factor alpha. FASEB J., 12(10), 871-880.
144. Ladner, K. J.; Caligiuri, M. A. and Guttridge, D. C. (2003) Tumor necrosis factor-regulated biphasic activation of NF-kappa B is required for cytokine-induced loss of skeletal muscle gene products. J. Biol. Chem., 278(4), 2294-2303.
145. Russell, S. T.; Eley, H. and Tisdale, M. J. (2007) Role of reactive oxygen species in protein degradation in murine myotubes induced by proteolysis-inducing factor and angiotensin II. Cell Signal., 19(8), 1797-1806.
146. Eley, H. L. and Tisdale, M. J. (2007) Skeletal muscle atrophy, a link between depression of protein synthesis and increase in degradation. J. Biol. Chem., 282(10), 7087-7097.
147. Eley, H. L.; Russell, S. T. and Tisdale, M. J. (2007) Attenuation of muscle atrophy in a murine model of cachexia by inhibition of the dsRNA-dependent protein kinase. Br. J. Cancer, 96(8), 1216-1222.
148. Eley, H. L.; Skipworth, R. J.; Deans, D. A.; Fearon, K. C. and Tisdale, M. J. (2008) Increased expression of phosphorylated forms of RNA-dependent protein kinase and eukaryotic initiation factor 2alpha may signal skeletal muscle atrophy in weight-losing cancer patients. Br. J. Cancer, 98(2), 443-449.
149. Eley, H. L.; Russell, S. T. and Tisdale, M. J. (2008) Attenuation of depression of muscle protein synthesis induced by lipopolysaccharide, tumor necrosis factor, and angiotensin II by beta-hydroxy-beta-methylbutyrate. Am. J. Physiol. Endocrinol. Metab., 295(6), E1409-E1416.
150. Potthoff, M. J.; Arnold, M. A.; McAnally, J.; Richardson, J. A.; Bassel-Duby, R. and Olson, E. N. (2007) Regulation of skeletal muscle sarcomere integrity and postnatal muscle function by Mef2c. Mol. Cell Biol., 27(23), 8143-8151.
151. Sakuma, K.; Nakao, R.; Inashima, S.; Hirata, M.; Kubo, T. and Yasuhara, M. (2004) Marked reduction of focal adhesion kinase, serum response factor and myocyte enhancer factor 2C, but increase in RhoA and myostatin in the hindlimb dy mouse muscles. Acta Neuropathol., 108(3), 241-249.
152. Yamakuchi, M.; Higuchi, I.; Masuda, S.; Ohira, Y.; Kubo, T.; Kato, Y.; Maruyama, I. and Kitajima, I. (2000) Type I muscle atrophy caused by microgravity-induced decrease of myocyte enhancer factor 2C (MEF2C) protein expression. FEBS Lett., 477(1-2), 135-140.
153. Lebrun, P.; Cognard, E.; Bellon-Paul, R.; Gontard, P.; Filloux, C.; Jehl-Pietri, C.; Grimaldi, P.; Samson, M.; Penicaud, L.; Ruberte, J.; Ferre, T.; Pujol, A.; Bosch, F. and Van Obberghen, E. (2009) Constitutive expression of suppressor of cytokine signalling-3 in skeletal muscle leads to reduced mobility and overweight in mice. Diabetologia, 52(10), 2201-2212.
154. Olson, E. N. and Williams, R. S. (2000) Remodeling muscles with calcineurin. Bioessays, 22(6), 510-519.
155. Liu, D.; Kang, J. S. and Derynck, R. (2004) TGF-beta-activated Smad3 represses MEF2-dependent transcription in myogenic differentiation. EMBO J., 23(7), 1557-1566.
156. Ceglia, L. (2008) Vitamin D and skeletal muscle tissue and function. Mol. Aspects Med., 29(6), 407-414.
157. Endo, I.; Inoue, D.; Mitsui, T.; Umaki, Y.; Akaike, M.; Yoshizawa, T.; Kato, S. and Matsumoto, T. (2003) Deletion of vitamin D receptor gene in mice results in abnormal skeletal muscle development with deregulated expression of myoregulatory transcription factors. Endocrinology, 144(12), 5138-5144.
158. Burne, T. H.; McGrath, J. J.; Eyles, D. W. and Mackay-Sim, A. (2005) Behavioural characterization of vitamin D receptor knockout mice. Behav. Brain Res., 157(2), 299-308.
159. Burne, T. H.; Johnston, A. N.; McGrath, J. J. and Mackay-Sim, A. (2006) Swimming behaviour and post-swimming activity in Vitamin D receptor knockout mice. Brain Res. Bull, 69(1), 74-78.
160. Grundberg, E.; Brandstrom, H.; Ribom, E. L.; Ljunggren, O.; Mallmin, H. and Kindmark, A. (2004) Genetic variation in the human vitamin D receptor is associated with muscle strength, fat mass and body weight in Swedish women. Eur. J. Endocrinol., 150(3), 323-328.
161. Roth, S. M.; Zmuda, J. M.; Cauley, J. A.; Shea, P. R. and Ferrell, R. E. (2004) Vitamin D receptor genotype is associated with fatfree mass and sarcopenia in elderly men. J. Gerontol. A. Biol. Sci. Med. Sci., 59(1), 10-15.
162. Geusens, P.; Vandevyver, C.; Vanhoof, J.; Cassiman, J. J.; Boonen, S. and Raus, J. (1997) Quadriceps and grip strength are related to vitamin D receptor genotype in elderly nonobese women. J. Bone Miner Res., 12(12), 2082-2088.
163. Bahat, G.; Saka, B.; Erten, N.; Ozbek, U.; Coskunpinar, E.; Yildiz, S.; Sahinkaya, T. and Karan, M. A. (2010) BsmI polymorphism in the vitamin D receptor gene is associated with leg extensor muscle strength in elderly men. Aging Clin. Exp. Res., 22(3), 198-205.
164. Wang, P.; Ma, L. H.; Wang, H. Y.; Zhang, W.; Tian, Q.; Cao, D. N.; Zheng, G. X. and Sun, Y. L. (2006) Association between polymorphisms of vitamin D receptor gene ApaI, BsmI and TaqI and muscular strength in young Chinese women. Int. J. Sports Med., 27(3), 182-186.
165. Pfeifer, M.; Begerow, B.; Minne, H. W.; Suppan, K.; Fahrleitner-Pammer, A. and Dobnig, H. (2009) Effects of a long-term vitamin D and calcium supplementation on falls and parameters of muscle function in community-dwelling older individuals. Osteoporos Int., 20(2), 315-322.
166. Haugen, B. R.; Jensen, D. R.; Sharma, V.; Pulawa, L. K.; Hays, W. R.; Krezel, W.; Chambon, P. and Eckel, R. H. (2004) Retinoid X receptor gamma-deficient mice have increased skeletal muscle lipoprotein lipase activity and less weight gain when fed a high-fat diet. Endocrinology, 145(8), 3679-3685.
167. Mangelsdorf, D. J.; Borgmeyer, U.; Heyman, R. A.; Zhou, J. Y.; Ong, E. S.; Oro, A. E.; Kakizuka, A. and Evans, R. M. (1992) Characterization of three RXR genes that mediate the action of 9-cis retinoic acid. Genes Dev., 6(3), 329-344.
168. Brown, N. S.; Smart, A.; Sharma, V.; Brinkmeier, M. L.; Greenlee, L.; Camper, S. A.; Jensen, D. R.; Eckel, R. H.; Krezel, W.; Chambon, P. and Haugen, B. R. (2000) Thyroid hormone resistance and increased metabolic rate in the RXR-gammadeficient mouse. J. Clin. Invest., 106(1), 73-79.
169. Muscat, G. E.; Mynett-Johnson, L.; Dowhan, D.; Downes, M. and Griggs, R. (1994) Activation of myoD gene transcription by 3,5,3'-triiodo-L-thyronine: a direct role for the thyroid hormone and retinoid X receptors. Nucleic Acids Res., 22(4), 583-591.
170. Kamei, Y.; Miura, S.; Suganami, T.; Akaike, F.; Kanai, S.; Sugita, S.; Katsumata, A.; Aburatani, H.; Unterman, T. G.; Ezaki, O. and Ogawa, Y. (2008) Regulation of SREBP1c gene expression in skeletal muscle: role of retinoid X receptor/liver X receptor and forkhead-O1 transcription factor. Endocrinology, 149(5), 2293-2305.
171. Lau, P.; Nixon, S. J.; Parton, R. G. and Muscat, G. E. (2004) RORalpha regulates the expression of genes involved in lipid homeostasis in skeletal muscle cells: caveolin-3 and CPT-1 are direct targets of ROR. J. Biol. Chem., 279(35), 36828-36840.
172. Lau, P.; Bailey, P.; Dowhan, D. H. and Muscat, G. E. (1999) Exogenous expression of a dominant negative RORalpha1 vector in muscle cells impairs differentiation: RORalpha1 directly interacts with p300 and myoD. Nucleic Acids Res., 27(2), 411-420.